OBJECTIVE: to evaluate the diagnostic potential of a panel of microRNAs in plasma samples of patients with malignant pleural mesothelioma (MPM). METHODS: a group of patients with pathological diagnosis of MPM were randomly selected from a prospective mesothelioma database. Similarly, a group of patients with asbestosis and one with benign pulmonary disease, were chosen for comparison. A panel of miRNA including miR-16, miR-17, miR-21, miR-126 and miR-486 were evaluated. VEGF (vascular endothelial growth factor) was evaluated in plasma samples of patients with mesothelioma. Analysis of covariance (ANCOVA) followed by Bonferroni post-hoc test were used for multiple comparisons. P<0.05 was considered significant. RESULTS: 14 patients with malignant pleural mesothelioma, 14 patients with asbestosis and 21 patients with benign pulmonary disease were studied. The expression of miR-16 (p=0.018), miR-17 (p=0.024) and miR-126 (p=0.019) was significantly lower in patients with MPM compared with patients with benign pulmonary disease. Interestingly, miR-486 was able to discriminate patients with MPM compared to patients with asbestosis (p=0.004). Considering patients with MPM, miR-17 (p=0.023) and miR-486 (p=0.015) were significantly more expressed in patients with epithelial type than in patients with sarcomatoid and biphasic type. Moreover, the expression of miR-16 (p<0.0001), miR-17 (p<0.0001), miR-21 (p=0.004), miR-126 (p=0.0016) and miR-486 (p=0.003) was significantly lower in patients with asbestosis compared with subjects with benign pulmonary disease. In MPM plasma samples, VEGF expression was negatively correlated to miR-126 (p=0.004). CONCLUSIONS: the expression of miR-16, miR-17 and miR-126 was able to distinguish patients with MPM compared with patients with benign pulmonary diseases. miR-17 and miR-486 were significantly higher in patients with epithelial mesothelioma. An immunohistochemistry analysis evaluating the expression of VEGF in MPM tissue samples is ongoing. The available data support the role of miRNAs in the aetiology of MPM, suggesting their possible use as diagnostic markers of the disease.

microRNAs Expression in Malignant Pleural Mesothelioma, Asbestosis and Benign Pulmonary Disease / Ampollini, Luca; Mozzoni, Paola; Gnetti, Letizia; Tiseo, Marcello; Rolli, Luigi; Solinas, Michela; Ventura, Luigi; Enrico Maria Silini, ; Goldoni, Matteo; Alinovi, Rossella; Rusca, Michele; Corradi, Massimo; Carbognani, Paolo; Mutti, Antonio. - ELETTRONICO. - (2015). ((Intervento presentato al convegno 16th World Conference on Lung Cancer IASLC tenutosi a DENVER - Colorado - USA nel 6-9 settembre 2015.

microRNAs Expression in Malignant Pleural Mesothelioma, Asbestosis and Benign Pulmonary Disease

AMPOLLINI, Luca;MOZZONI, Paola;Tiseo, Marcello;VENTURA, LUIGI;SILINI, Enrico Maria;GOLDONI, Matteo;ALINOVI, Rossella;RUSCA, Michele;CORRADI, Massimo;CARBOGNANI, Paolo;MUTTI, Antonio
2015

Abstract

OBJECTIVE: to evaluate the diagnostic potential of a panel of microRNAs in plasma samples of patients with malignant pleural mesothelioma (MPM). METHODS: a group of patients with pathological diagnosis of MPM were randomly selected from a prospective mesothelioma database. Similarly, a group of patients with asbestosis and one with benign pulmonary disease, were chosen for comparison. A panel of miRNA including miR-16, miR-17, miR-21, miR-126 and miR-486 were evaluated. VEGF (vascular endothelial growth factor) was evaluated in plasma samples of patients with mesothelioma. Analysis of covariance (ANCOVA) followed by Bonferroni post-hoc test were used for multiple comparisons. P<0.05 was considered significant. RESULTS: 14 patients with malignant pleural mesothelioma, 14 patients with asbestosis and 21 patients with benign pulmonary disease were studied. The expression of miR-16 (p=0.018), miR-17 (p=0.024) and miR-126 (p=0.019) was significantly lower in patients with MPM compared with patients with benign pulmonary disease. Interestingly, miR-486 was able to discriminate patients with MPM compared to patients with asbestosis (p=0.004). Considering patients with MPM, miR-17 (p=0.023) and miR-486 (p=0.015) were significantly more expressed in patients with epithelial type than in patients with sarcomatoid and biphasic type. Moreover, the expression of miR-16 (p<0.0001), miR-17 (p<0.0001), miR-21 (p=0.004), miR-126 (p=0.0016) and miR-486 (p=0.003) was significantly lower in patients with asbestosis compared with subjects with benign pulmonary disease. In MPM plasma samples, VEGF expression was negatively correlated to miR-126 (p=0.004). CONCLUSIONS: the expression of miR-16, miR-17 and miR-126 was able to distinguish patients with MPM compared with patients with benign pulmonary diseases. miR-17 and miR-486 were significantly higher in patients with epithelial mesothelioma. An immunohistochemistry analysis evaluating the expression of VEGF in MPM tissue samples is ongoing. The available data support the role of miRNAs in the aetiology of MPM, suggesting their possible use as diagnostic markers of the disease.
microRNAs Expression in Malignant Pleural Mesothelioma, Asbestosis and Benign Pulmonary Disease / Ampollini, Luca; Mozzoni, Paola; Gnetti, Letizia; Tiseo, Marcello; Rolli, Luigi; Solinas, Michela; Ventura, Luigi; Enrico Maria Silini, ; Goldoni, Matteo; Alinovi, Rossella; Rusca, Michele; Corradi, Massimo; Carbognani, Paolo; Mutti, Antonio. - ELETTRONICO. - (2015). ((Intervento presentato al convegno 16th World Conference on Lung Cancer IASLC tenutosi a DENVER - Colorado - USA nel 6-9 settembre 2015.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11381/2816226
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact